Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor.
Gillespie G, Jackson Rudd D, Zhang S, Schaeffer A, Tomek C, Larson P, Stoch SA, Iwamoto M. Gillespie G, et al. Among authors: iwamoto m. J Clin Pharmacol. 2022 Feb;62(2):199-205. doi: 10.1002/jcph.1957. Epub 2021 Nov 12. J Clin Pharmacol. 2022. PMID: 34435371 Free PMC article. Clinical Trial.
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA. McCrea JB, et al. Among authors: iwamoto m. Clin Pharmacol Ther. 2003 Jul;74(1):17-24. doi: 10.1016/S0009-9236(03)00066-3. Clin Pharmacol Ther. 2003. PMID: 12844131 Clinical Trial.
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M. Anderson MS, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6. Antimicrob Agents Chemother. 2008. PMID: 18838586 Free PMC article. Clinical Trial.
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M. Wenning LA, et al. Among authors: iwamoto m. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279563 Clinical Trial.
Effect of raltegravir on the pharmacokinetics of methadone.
Anderson MS, Mabalot Luk JA, Hanley WD, Jin B, Riesenberg RA, Wenning LA, Chodakewitz JA, Wagner JA, Iwamoto M. Anderson MS, et al. Among authors: iwamoto m. J Clin Pharmacol. 2010 Dec;50(12):1461-6. doi: 10.1177/0091270009360981. Epub 2010 Feb 19. J Clin Pharmacol. 2010. PMID: 20173085 Clinical Trial.
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, Stone JA, Chodakewitz JA, Wagner JA, Iwamoto M. Brainard DM, et al. Among authors: iwamoto m. J Clin Pharmacol. 2011 Mar;51(3):422-7. doi: 10.1177/0091270010367652. Epub 2010 May 10. J Clin Pharmacol. 2011. PMID: 20457591 Clinical Trial. No abstract available.
Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Brainard DM, Kassahun K, Wenning LA, Petry AS, Liu C, Lunceford J, Hariparsad N, Eisenhandler R, Norcross A, DeNoia EP, Stone JA, Wagner JA, Iwamoto M. Brainard DM, et al. Among authors: iwamoto m. J Clin Pharmacol. 2011 Jun;51(6):943-50. doi: 10.1177/0091270010375959. Epub 2010 Sep 17. J Clin Pharmacol. 2011. PMID: 20852006 Clinical Trial.
1,449 results